U.S. Markets closed

AstraZeneca PLC (AZN.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
5,089.00-63.00 (-1.22%)
At close: 4:35PM BST
Full screen
Previous Close5,152.00
Open5,147.00
Bid5,050.00 x 6100
Ask5,200.00 x 13000
Day's Range5,055.00 - 5,154.00
52 Week Range3,996.00 - 5,520.00
Volume2,477,829
Avg. Volume1,964,627
Market Cap64.41B
Beta0.67
PE Ratio (TTM)19.06
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (4.24%)
Ex-Dividend Date2017-02-16
1y Target EstN/A
  • Financial Times2 days ago

    [$$] GSK chief plans to shake up culture and competitiveness

    When Emma Walmsley addressed GSK's 100,000-strong global workforce for the first time this year, employees gathered to hear the new chief executive explain her strategy noticed a striking contrast with ...

  • Biotechs On A Hot Streak, And Could Be 'Cooking With Gas'
    Investor's Business Daily3 days ago

    Biotechs On A Hot Streak, And Could Be 'Cooking With Gas'

    IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?

  • Reuters3 days ago

    GlaxoSmithKline's new CEO prepares to trim drug pipeline

    GlaxoSmithKline's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.